Cyberonics Stays Neutral - Analyst Blog
September 30 2011 - 6:00AM
Zacks
We recently reiterated our Neutral
recommendation on Cyberonics (CYBX) with a target
price of $29.00, following our assessment of its first quarter 2012
results.
Cyberonics reported first quarter
2012 EPS of 28 cents, which surpassed the Zacks Consensus Estimate
of 26 cents and was 12% higher than the year-ago quarter’s adjusted
EPS.
Cyberonics develops and markets
Vagus Nerve Stimulation (VNS) Therapy System, which is approved by
the US Food and Drug Administration (FDA) for the treatment of
refractory epilepsy and treatment-resistant depression (TRD).
During the quarter, Cyberonics
witnessed continuous expansion in its top line, attributable to the
company’s pioneer product, VNS Therapy System, especially indicated
for the treatment of epilepsy.
During the reported quarter,
Epilepsy unit sales increased 6% in the US to 1,060 units on the
back of both new patients and replacements. This was strongly
driven by higher volume and increased average selling prices. This
reflects a 97% upside in revenues within a span of four years. The
company continues to expect US replacements to increase 10% to
approximately 4,500 units in fiscal 2012.
The company is currently
emphasizing on its international business by expanding its epilepsy
portfolio through direct sales force and distributors in Canada and
Europe. Cyberonics also intends to expand its epilepsy business in
Latin America (including Brazil), Russia, Australia and Asia
(including Japan, China, India and Taiwan), where it sees huge
growth potential. The regulatory bodies in these countries
have approved VNS Therapy for the treatment of epilepsy without any
age restrictions or seizure-type limitation. During the first
quarter of fiscal 2012, the company’s international revenue was
$8.9 million, and contributed 17% of the total revenue.
Moreover, the company is focusing
on research and development in the field of VNS Therapy for
patients with refractory epilepsy specifically, seizure detection,
responsive stimulation and associated technology.
Presently, Cyberonics retains a
Zacks #3 Rank (Hold) in the short term that corresponds with our
long-term ‘Neutral’ recommendation. The company faces mounting
third-party reimbursement issues along with stiff competition in
the neuromodulation space from players such as
Medtronic (MDT) and St. Jude Medical
Inc. (STJ). Both Medtronic and St. Jude Medical are
Zacks #3 ranked peers with Neutral recommendations.
CYBERONICS INC (CYBX): Free Stock Analysis Report
MEDTRONIC (MDT): Free Stock Analysis Report
ST JUDE MEDICAL (STJ): Free Stock Analysis Report
Zacks Investment Research
SJM (NYSE:STJ)
Historical Stock Chart
From Jun 2024 to Jul 2024
SJM (NYSE:STJ)
Historical Stock Chart
From Jul 2023 to Jul 2024